Invesco S&P International Developed Quality ETF
- ETF
- Ticker IDHQ
- NYSE
Performance, volatility and drawdowns of Invesco S&P International Developed Quality ETF since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $27,406. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −33.5% in 09/2022, measured from the peak in 09/2021. It took 30 months to get back to the old peak.
Factor profile
Monthly returns 12/2016 to 09/2026, measured against Developed markets ex US. The factors explain 93% of the variation.
- Market
- 1.00
- Size
- −0.34
- Value
- −0.18
- Profitability
- 0.26
- Low investment
- −0.09
- Momentum
- 0.14
How to read this: IDHQ moves about as much as the stock market (Developed markets ex US). The ETF leans towards large companies and highly valued growth stocks.
A value of 1 for the market means: when the market rises by 1%, the ETF rises by 1% on average. The other values show the lean towards small, cheaply valued, profitable, conservatively investing and recently strong stocks; bold where it is clear. Calculated with the Fama and French factors and momentum.
Annual returns
Best year 2019 at +29.6%, weakest 2022 at −20.2%. 7 of 9 full years were positive. * partial year.
Similar ETFs
Frequently asked questions
How has IDHQ performed since 11/2016?
$10,000 grew to $27,406 by 20 Nov 2026, which is +10.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is IDHQ?
Volatility was 16.1% per year, measured on monthly returns. The largest decline from a peak was −33.5%, with the low in 09/2022.
How does IDHQ compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, IDHQ returned +10.6% at 16.1%. The correlation of monthly returns was 0.90; 1 would mean they moved in lockstep.
What does IDHQ hold?
IDHQ holds 198 positions. The largest are Roche Holding AG, ASML Holding N.V. and Novartis AG; the 10 largest together make up 32.1% of the fund (holdings as of 31 Jul 2026, according to the fund's filing with the SEC).
Which currency are the figures in?
In US dollars, the currency of the US listing.